A megakaryocyte with no platelets: Anti-platelet antibodies, apoptosis, and platelet production

Platelets

Volumn 24, Issue 2, 2013, Pages 98-106

  Perdomo, José ^a,b   Yan, Feng ^a,b   Chong, Beng H ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Megakaryocytes, apoptosis, anti platelet antibodies, immune thrombocytopenia, drug induced thrombocytopenia, platelet production

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CASPASE 3; CASPASE 9; CYTOCHROME C; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN 14 3 3; PROTEIN BAD; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; QUININE; REACTIVE OXYGEN METABOLITE; THROMBIN RECEPTOR; THROMBOCYTE ANTIBODY; THROMBOCYTE ANTIGEN; THROMBOCYTE FACTOR; THROMBOCYTE RECEPTOR; TRANSCRIPTION FACTOR FKHRL1; VON WILLEBRAND FACTOR;

APOPTOSIS; BONE MARROW; CELL DESTRUCTION; CELL DIFFERENTIATION; DRUG INDUCED DISEASE; GENE MUTATION; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IN VITRO STUDY; MEGAKARYOCYTE; MEGAKARYOPOIESIS; MITOCHONDRIAL MEMBRANE POTENTIAL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RETICULOENDOTHELIAL SYSTEM; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS;

ANTIBODIES; APOPTOSIS; AUTOANTIBODIES; BLOOD PLATELETS; HUMANS; MEGAKARYOCYTES; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;

EID: 84873350464     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2012.669508     Document Type: Review

References (75)

1. Rodeghiero F, Besalduch J, Michel M, Provan D, Grotzinger K, Thompson G. Treatment practices in adults with chronic immune thrombocytopenia - A European perspective. Eur J Haematol 2010;84(2):160-168
2. George JN, Aster RH. Drug-induced thrombocytopenia: Pathogenesis, evaluation, and management. Hematology, American Society of Hematology, Education Program 2009; 153-158
3. Christie DJ, Aster RH. Drug-Antibody-platelet interaction in quinine- And quinidine-induced thrombocytopenia. J Clin Invest 1982;70(5):989-998 (Pubitemid 13254922)
4. Chong BH. Drug-induced immune thrombocytopenia. Platelets 1991;2(4):173-181
5. Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. New Engl J Med 2007;357(6):580-587 (Pubitemid 47236283)
6. Newland AC, Macey MG. Immune thrombocytopenia and Fc receptor-mediated phagocyte function. Ann Hematol 1994;69(2):61-67 (Pubitemid 24266964)
7. Olsson B, Andersson PO, Jernås M, Jacobsson S, Carlsson B, Carlsson LMS, Wadenvik H. T-Cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003;9(9):1123-1124 (Pubitemid 37173694)
8. Houwerzijl EJ, Blom NR, Van Der Want JJL, Esselink MT, Koornstra JJ, Smit JW, Louwes H, Vellenga E, De Wolf JTM. Ultrastructural study shows morphologic features of apoptosis and para-Apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood 2004; 103(2):500-506 (Pubitemid 38140080)
9. Stasi R, Evangelista ML, Stipa E, Buccisano F, Venditti A, Amadori S. Idiopathic thrombocytopenic purpura: Current concepts in pathophysiology and management. Thromb Haemost 2008;99(1):4-13
10. Stockelberg D, Hou M, Jacobsson S, Kutti J, Wadenvik H. Detection of platelet antibodies in chronic idiopathic thrombocytopenic purpura (ITP). A comparative study using flow cytometry, a whole platelet ELISA, and an antigen capture ELISA. Eur J Haematol 1996;56(1-2):72-77 (Pubitemid 26075598)
11. McMillan R. Autoantibodies and autoantigens in chronic immune thrombocytopenic purpura. Semin Hematol 2000;37(3):239-248 (Pubitemid 30612902)
12. Asvadi P, Ahmadi Z, Chong BH. Drug-induced thrombocytopenia: Localization of the binding site of GPIX-Specific quinine-Dependent antibodies. Blood 2003;102(5):1670-1677 (Pubitemid 37022559)
13. Visentin GP, Newman PJ, Aster RH. Characteristics of quinine- And quinidine-induced antibodies specific for platelet glycoproteins IIb and IIIa. Blood 1991; 77(12):2668-2676
14. Peterson JA, Nelson TN, Kanack AJ, Aster RH. Fine specificity of drug-Dependent antibodies reactive with a restricted domain of platelet GPIIIA. Blood 2008; 111(3):1234-1239 (Pubitemid 351213405)
15. Burgess JK, Lopez JA, Berndt MC, Dawes I, Chesterman CN, Chong BH. Quinine-Dependent antibodies bind a restricted set of epitopes on the glycoprotein Ib-IX complex: Characterization of the epitopes. Blood 1998;92(7):2366-2373 (Pubitemid 28452979)
16. Gao C, Boylan B, Bougie D, Gill JC, Birenbaum J, Newman DK, Aster RH, Newman PJ. Eptifibatide-induced thrombocytopenia and thrombosis in humans require FcgammaRIIa and the integrin beta3 cytoplasmic domain. J Clin Invest 2009;119(3):504-511
17. McKenzie SE, Taylor SM, Malladi P, Yuhan H, Cassel DL, Chien P, Schwartz E, Schreiber AD, Surrey S, Reilly MP. The role of the human Fc receptor FcOE-RIIA in the immune clearance of platelets: A transgenic mouse model. J Immunol 1999;162(7):4311-4318 (Pubitemid 29314823)
18. Tomer A. Human marrow megakaryocyte differentiation: Multiparameter correlative analysis identifies von Willebrand factor as a sensitive and distinctive marker for early (2N and 4N) megakaryocytes. Blood 2004;104(9):2722-2727 (Pubitemid 39434953)
19. Vazquez JJ, Lewis JH. Immunocytochemical studies on platelets. The demonstration of a common antigen in human platelets and megakaryocytes. Blood 1960; 16:968-974
20. De Laval M. Mise en evidence d'antigenes plaquettaires dans le cytoplasme des megacaryocytes par la technique des anticorps fluorescents. CR SOC Biol (Paris) 1967; 161:948-951
21. Stahl CP, Zucker-Franklin D, McDonald TP. Incomplete antigenic cross-reactivity between platelets and megakaryocytes: Relevance to ITP. Blood 1986;67(2):421-428 (Pubitemid 16164659)
22. Vinci G, Tabilio A, Deschamps JF. Immunological study of in vitro maturation of human megakaryocytes. Br J Haematol 1984;56(4):589-605 (Pubitemid 14128136)
23. Mazur EM, Hoffman R, Chasis J. Immunofluorescent identification of human megakaryocyte colonies using an antiplatelet glycoprotein antiserum. Blood 1981;57(2):277-286 (Pubitemid 11174889)
24. McMillan R, Luiken GA, Levy R. Antibody against megakaryocytes in idiopathic thrombocytopenic purpura. JAMA 1978;239(23):2460-2462 (Pubitemid 8369700)
25. Perdomo J, Yan F, Ahmadi Z, Jiang XM, Stocker R, Chong BH. Quinine-induced thrombocytopenia: Drugdependent GPIb/IX antibodies inhibit megakaryocyte and proplatelet production in vitro. Blood 2011; 117(22):5975-5986
26. Hoffman R, Zaknoen S, Yang HH. An antibody cytotoxic to megakaryocyte progenitor cells in a patient with immune thrombocytopenic purpura. New Engl J Med 1985;312(18):1170-1174 (Pubitemid 15008034)
27. Chang M, Nakagawa PA, Williams SA, Schwartz MR, Imfeld KL, Buzby JS, Nugent DJ. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood 2003;102(3):887-895 (Pubitemid 36917780)
28. McMillan R, Wang L, Tomer A, Nichol J, Pistillo J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood 2004;103(4):1364-1369 (Pubitemid 38168649)
29. Balduini A, Pallotta I, Malara A, Lova P, Pecci A, Viarengo G, Balduini CL, Torti M. Adhesive receptors, extracellular proteins and myosin IIA orchestrate proplatelet formation by human megakaryocytes. J Thromb Haemost 2008;6(11): 1900-1907
30. Takahashi R, Sekine N, Nakatake T. Influence of monoclonal antiplatelet glycoprotein antibodies on in vitro human megakaryocyte colony formation and proplatelet formation. Blood 1999;93(6):1951-1958 (Pubitemid 29128497)
31. Greinacher A, Fuerll B, Zinke H, Mullejans B, Kruger W, Michetti N, Motz W, Schwertz H. Megakaryocyte impairment by eptifibatide-induced antibodies causes prolonged thrombocytopenia. Blood 2009;114(6):1250-1253
32. Kaushansky K. Determinants of platelet number and regulation of thrombopoiesis. Hematology, American Society of Hematology, Education Program 2009;147-152
33. Li J, Kuter DJ. The end is just the beginning: Megakaryocyte apoptosis and platelet release. Int J Hematol 2001;74(4): 365-374 (Pubitemid 33760096)
34. White MJ, Kile BT. Apoptotic processes in megakaryocytes and platelets. Semin Hematol 2010;47(3):227-234
35. De Botton S, Sabri S, Daugas E, Zermati Y, Guidotti JE, Hermine O, Kroemer G, Vainchenker W, Debili N. Platelet formation is the consequence of caspase activation within megakaryocytes. Blood 2002;100(4):1310-1317 (Pubitemid 34864286)
36. Clarke MCH, Savill J, Jones DB, Noble BS, Brown SB. Compartmentalized megakaryocyte death generates functional platelets committed to caspase-independent death. J Cell Biol 2003;160(4):577-587 (Pubitemid 36254395)
37. Yang L, Wang L, Zhao CH, Zhu XJ, Hou Y, Peng J, Hou M. Contributions of TRAIL-mediated megakaryocyte apoptosis to impaired megakaryocyte and platelet production in immune thrombocytopenia. Blood 2010;116(20):4307-4316
38. Ogilvy S, Metcalf D, Print CG, Bath ML, Harris AW, Adams JM. Constitutive Bcl-2 expression throughout the hematopoietic compartment affects multiple lineages and enhances progenitor cell survival. Proc Natl Acad Sci USA 1999;96(26):14943-14948 (Pubitemid 30019744)
39. Bouillet P, Metcalf D, Huang DCS, Tarlinton DM, Kay TWH, Köntgen F, Adams JM, Strasser A. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 1999;286(5445):1735-1738 (Pubitemid 129515880)
40. Kozuma Y, Yuki S, Ninomiya H, Nagasawa T, Kojima H. Caspase activation is involved in early megakaryocyte differentiation but not in platelet production from megakaryocytes. Leukemia 2009;23(6):1080-1086
41. Josefsson EC, James C, Henley KJ, Debrincat MA, Rogers KL, Dowling MR, White MJ, Kruse EA, Lane RM, Ellis S, et al. Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets. J Exp Med 2011;208(10):2017-2031
42. Morison IM, Cramer Borde EM, Cheesman EJ, Cheong PL, Holyoake AJ, Fichelson S, Weeks RJ, Lo A, Davies SMK, Wilbanks SM, et al. A mutation of human cytochrome c enhances the intrinsic apoptotic pathway but causes only thrombocytopenia. Nat Genet 2008;40(4):387-389 (Pubitemid 351450877)
43. Wagner KU, Claudio E, Rucker EB, Riedlinger G, Broussard C, Schwartzberg PL, Siebenlist U, Hennighausen L. Conditional deletion of the Bcl-x gene from erythroid cells results in hemolytic anemia and profound splenomegaly. Development 2000;127(22):4949-4958
44. Kaluzhny Y, Yu G, Sun S, Toselli PA, Nieswandt B, Jackson CW, Ravid K. BclxL overexpression in megakaryocytes leads to impaired platelet fragmentation. Blood 2002; 100(5):1670-1678 (Pubitemid 34925144)
45. Zauli G, Catani L, Gibellini D, Carla Re M, Vianelli N, Colangeli V, Celeghini C, Capitani S, La Placa M. Impaired survival of bone marrow GPIIb/IIIa megakaryocytic cells as an additional pathogenetic mechanism of HIV-1-related thrombocytopenia. Br J Haematol 1996;92(3):711-717 (Pubitemid 26076772)
46. Pisciotta AV, Stefanini M, Dameshek W. Studies on platelets. X. Morphologic characteristics of megakaryocytes by phase contrast microscopy in normals and in patients with idiopathic thrombocytopenic purpura. Blood 1953;8(8):703-723
47. Wentworth AD, Jones LH, Wentworth Jr P, Janda KD, Lerner RA. Antibodies have the intrinsic capacity to destroy antigens. Proc Natl Acad Sci USA 2000; 97(20):10930-10935
48. Dumont A, Hehner SP, Hofmann TG, Ueffing M, Dröge W, Schmitz ML. Hydrogen peroxide-induced apoptosis is CD95-independent, requires the release of mitochondria-Derived reactive oxygen species and the activation of NF-kB. Oncogene 1999;18(3):747-757 (Pubitemid 29080332)
49. Lopez JJ, Salido GM, Go'mez-Arteta E, Rosado JA, Pariente JA. Thrombin induces apoptotic events through the generation of reactive oxygen species in human platelets. J Thromb Haemost 2007;5(6):1283-1291 (Pubitemid 46902132)
50. Nardi M, Tomlinson S, Greco MA, Karpatkin S. Complement-independent, peroxide-induced antibody lysis of platelets in HIV-1-related immune thrombocytopenia. Cell 2001;106(5):551-561 (Pubitemid 32879317)
51. Arthur JF, Shen Y, Gardiner EE, Coleman L, Kenny D, Andrews RK, Berndt MC. TNF receptor-Associated factor 4 (TRAF4) is a novel binding partner of glycoprotein Ib and glycoprotein VI in human platelets. J Thromb Haemost 2011;9(1):163-172
52. Pathan NI, Chu P, Hariharan K, Cheney C, Molina A, Byrd J. Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23 lymphoma cell lines. Blood 2008;111(3):1594-1602 (Pubitemid 351213450)
53. Du X, Fox JE, Pei S. Identification of a binding sequence for the 14-3-3 protein within the cytoplasmic domain of the adhesion receptor, platelet glycoprotein Iba. J Biol Chem 1996;271(13):7362-7367 (Pubitemid 26107003)
54. Mu FT, Andrews RK, Arthur JF, Munday AD, Cranmer SL, Jackson SP, Stomski FC, Lopez AF, Berndt MC. A functional 14-3-3{zeta}-independent association of PI3-kinase with glycoprotein Ib{alpha}, the major ligand-binding subunit of the platelet glycoprotein Ib-IX-V complex. Blood 2008; 111(9):4580-4587
55. Subramanian RR, Masters SC, Zhang H, Fu H. Functional conservation of 14-3-3 isoforms in inhibiting Bad-induced apoptosis. Exp Cell Res 2001;271(1):142-151 (Pubitemid 33071001)
56. Nomura M, Shimizu S, Sugiyama T, Narita M, Ito T, Matsuda H, Tsujimoto Y. 14-3-3 Interacts directly with and negatively regulates pro-Apoptotic Bax. J Biol Chem 2003;278(3):2058-2065 (Pubitemid 36801450)
57. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005;4(12):988-1004
58. Li S, Wang Z, Liao Y, Zhang W, Shi Q, Yan R, Ruan C, Dai K. The glycoprotein Ibalpha-Von Willebrand factor interaction induces platelet apoptosis. J Thromb Haemost 2010;8(2):341-350
59. Van Der Wal DE, Du VX, Lo KSL, Rasmussen JT, Verhoef S, Akkerman JWN. Platelet apoptosis by coldinduced glycoprotein Ib{alpha} clustering. J Thromb Haemost 2010;8(11):2554-2562
60. Piguet PF, Vesin C. Modulation of platelet caspases and lifespan by anti-platelet antibodies in mice. Eur J Haematol 2002;68(5):253-261
61. Cunningham JG, Meyer SC, Fox JEB. The cytoplasmic domain of the GPIba-Subunit of glycoprotein (GP) Ib mediates attachment of the entire GP Ib-IX complex to the cytoskeleton and regulates von Willebrand factor-induced changes in cell morphology. J Biol Chem 1996; 271(19):11581-11587
62. Poujol C, Ware J, Nieswandt B, Nurden AT, Nurden P. Absence of GPIbalpha is responsible for aberrant membrane development during megakaryocyte maturation: Ultrastructural study using a transgenic model. Exp Hematol 2002;30(4):352-360 (Pubitemid 34286441)
63. Mehta YS, Pathare AV, Badakere SS, Ghosh K, Mohanty D. Influence of auto-Antibody specificities on the clinical course in patients with chronic and acute ITP. Platelets 2000;11(2):94-98 (Pubitemid 30224417)
64. Go RS, Johnston KL, Bruden KC. The association between platelet autoantibody specificity and response to intravenous immunoglobulin G in the treatment of patients with immune thrombocytopenia. Haematologica 2007;92(2):283-284 (Pubitemid 46852445)
65. Webster ML, Sayeh E, Crow M, Chen P, Nieswandt B, Freedman J, Ni H. Relative efficacy of intravenous immunoglobulin G in ameliorating thrombocytopenia induced by antiplatelet GPIIbIIIa versus GPIbalpha antibodies. Blood 2006;108(3):943-946 (Pubitemid 44154629)
66. Liang SX, Pinkevych M, Khachigian LM, Parish CR, Davenport MP, Chong BH. Drug-induced thrombocytopenia: Development of a novel NOD/SCID mouse model to evaluate clearance of circulating platelets by drug-Dependent antibodies and the efficacy of IVIG. Blood 2010; 116(11):1958-1960
67. Choi CW, Kim BS, Seo JH, Shin SW, Kim YH, Kim JS, Sohn SK, Shin DG, Ryoo HM, Lee KH, et al. Response to high-Dose intravenous immune globulin as a valuable factor predicting the effect of splenectomy in chronic idiopathic thrombocytopenic purpura patients. Am J Hematol 2001;66(3):197-202 (Pubitemid 32167457)
68. Holt D, Brown J, Terrill K, Goldsby R, Meyers RL, Heximer J, Nordfors B, Slayton WB. Response to intravenous immunoglobulin predicts splenectomy response in children with immune thrombocytopenic purpura. Pediatrics 2003;111(1):87-90 (Pubitemid 36071036)
69. Hansen RJ, Balthasar JP. Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia. Blood 2002;100(6):2087-2093 (Pubitemid 35001242)
70. Barsam SJ, Psaila B, Forestier M, Page LK, Sloane PA, Geyer JT, Villarica GO, Ruisi MM, Gernsheimer TB, Beer JH, et al. Platelet production and platelet destruction: Assessing mechanisms of treatment effect in immune thrombocytopenia (ITP). Blood 2011;117(21):5723-5732
71. Kuter DJ. Biology and chemistry of thrombopoietic agents. Semin Hematol 2010;47(3):243-248
72. Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, Chong BH, Cines DB, Gernsheimer TB, Godeau B, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115(2):168-186
73. Gardiner EE, Thom JY, Al-Tamimi M, Hughes A, Berndt MC, Andrews RK, Baker RI. Restored platelet function after romiplostim treatment in a patient with immune thrombocytopenic purpura. Br J Haematol 2010;149(4):625-628
74. Alimardani G, Guichard J, Fichelson S, Cramer EM. Pathogenic effects of anti-glycoprotein Ib antibodies on megakaryocytes and platelets. Thromb Haemost 2002; 88(6):1039-1046 (Pubitemid 36018793)
75. Basu S, Totty NF, Irwin MS, Sudol M, Downward J. Akt phosphorylates the Yes-Associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol. Cell 2003;11(1):11-23 (Pubitemid 36126587)